This inventor holds 15 USPTO granted patents and 4 EPO patents. Top assignees: Chiesi Farmaceutici S.p.a., Glaxo Group Limited, Pulmagen Therapeutics (Inflammation) Limited. Active years: 2011-2023.
Location History:
- Flex Meadow, GB (2013)
- Harlow, GB (2011 - 2015)
- Essex, GB (2012 - 2015)
- Saffron Walden, GB (2019 - 2021)
- Parma, IT (2021 - 2023)
Company Filing History:
13 out of 340 
1 out of 1,169 
1 out of 5 Years Active: 2011-2023
Title: Christine Edwards: Innovator in Rho-Kinase Inhibition
Introduction
Christine Edwards is a prominent inventor based in Saffron Walden, GB. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit Rho Kinase. With a total of 15 patents to her name, her work has the potential to impact the treatment of various pulmonary diseases.
Latest Patents
One of her latest patents is focused on meta tyrosine derivatives as Rho-kinase inhibitors. This invention relates to compounds that inhibit Rho Kinase, specifically meta tyrosine derivatives. The patent outlines processes for preparing these compounds, pharmaceutical compositions containing them, and their therapeutic uses. These compounds may be particularly useful in treating disorders associated with ROCK enzyme mechanisms, such as asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary arterial hypertension (PAH).
Another significant patent involves oxadiazole derivatives as Rho-Kinase inhibitors. Similar to her previous work, this invention details compounds that inhibit Rho Kinase, specifically oxadiazole derivatives. The patent includes processes for preparing these compounds, pharmaceutical compositions, and their therapeutic applications. These compounds also hold promise for treating various pulmonary diseases linked to ROCK enzyme mechanisms.
Career Highlights
Throughout her career, Christine has worked with notable companies in the pharmaceutical industry. She has been associated with Chiesi Farmaceutici S.p.a. and Pulmagen Therapeutics (Inflammation) Limited. Her work in these organizations has contributed to her expertise in developing innovative therapeutic solutions.
Collaborations
Christine has collaborated with esteemed colleagues, including Alessandro Accetta and Fabio Rancati. These partnerships have further enriched her research and development efforts in the field of Rho-Kinase inhibition.
Conclusion
Christine Edwards is a trailblazer in the realm of pharmaceutical innovations, particularly in the development of Rho-Kinase inhibitors. Her contributions have the potential to significantly advance the treatment of various pulmonary disorders.